CONCLUSION
We present here three unique clinical cases, each of which highlights
both advantages and limitations to the use of68Ga-DOTATATE PET, 18F-FDG PET, and123I-MIBG SPECT/CT in the evaluation of patients with
PPGL. In these patients, who frequently have complex clinical
manifestations of their disease, no single imaging technique can be
forwarded as the single “best test”. Rather, as the cases shown here
emphasize, different clinical considerations necessitate a customized
choice of functional imaging techniques. The proposed algorithm may
serve as a guideline for physicians when determining which of the
available imaging selections is best suited to an individual patient’s
care.
REFERENCES
1. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and
paraganglioma: an endocrine society clinical practice guideline. J
Clin Endocrinol Metab. 2014;99(6):1915-1942.
2. Crona J, Taieb D, Pacak K. New Perspectives on Pheochromocytoma and
Paraganglioma: Toward a Molecular Classification. Endocr Rev.2017;38(6):489-515.
3. NETSPOT (kit for the preparation of gallium Ga 68 dotatate
injection), for intravenous use Initial U.S. Approval: 2016. United
States Food and Drug Administration. Online Document. Published June,
2016. Accessed July 24, 2021. .
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208547s000lbl.pdf
4. McElroy KM, Binkovitz LA, Trout AT, et al. Pediatric applications of
Dotatate: early diagnostic and therapeutic experience. Pediatr
Radiol. 2020;50(7):882-897.
5. Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. Neuroendocrine tumor
recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology.2014;270(2):517-525.
6. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management
impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and
other somatostatin expressing tumours. J Med Imaging Radiat
Oncol. 2012;56(1):40-47.
7. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and
negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.J Nucl Med. 2010;51(6):875-882.
8. Win Z, Al-Nahhas A, Towey D, et al. 68Ga-DOTATATE PET in
neuroectodermal tumours: first experience. Nucl Med Commun.2007;28(5):359-363.
9. Else T, Greenberg S, Fishbein L. Hereditary
Paraganglioma-Pheochromocytoma Syndromes. In: Adam MP, Ardinger HH,
Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
10. Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of
the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in
Patients with Neuroendocrine Tumors. J Nucl Med.2017;58(1):91-96.
11. Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG
PET and somatostatin receptor scintigraphy in patients with metastatic
endocrine tumors. J Nucl Med. 2009;50(6):858-864.
12. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose
[131I]metaiodobenzylguanidine therapy for patients with metastatic
pheochromocytoma and paraganglioma. J Clin Oncol.2009;27(25):4162-4168.
13. Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of
High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced
Pheochromocytoma or Paraganglioma. J Nucl Med.2019;60(5):623-630.
14. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C.
Gastrointestinal stromal tumor: role of CT in diagnosis and in response
evaluation and surveillance after treatment with imatinib.Radiographics. 2006;26(2):481-495.
15. Levy AD, Quiles AM, Miettinen M, Sobin LH. Gastrointestinal
schwannomas: CT features with clinicopathologic correlation. AJR
Am J Roentgenol. 2005;184(3):797-802.
16. Kamihara J, Hamilton KV, Pollard JA, et al. Use of belzutifan, a
potent HIF2a inhibitor, in a pediatric patient with Pacak-Zhuang
syndrome. NEJM. 2021;in press.
17. Chang CA, Pattison DA, Tothill RW, et al. (68)Ga-DOTATATE and
(18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility,
patterns and heterogeneity. Cancer Imaging. 2016;16(1):22.
18. Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and
algorithm for the genetic diagnosis of pheochromocytoma patients.Clin Cancer Res. 2009;15(20):6378-6385.
19. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer.Biochim Biophys Acta. 2011;1807(11):1432-1443.
20. Kroiss A, Shulkin BL, Uprimny C, et al. (68)Ga-DOTATOC PET/CT
provides accurate tumour extent in patients with extraadrenal
paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol
Imaging. 2015;42(1):33-41.
21. Maurice JB, Troke R, Win Z, et al. A comparison of the performance
of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis
and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl
Med Mol Imaging. 2012;39(8):1266-1270.
22. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES.
The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of
neuroendocrine tumors compared to current FDA approved imaging
modalities: a review of literature. Am J Nucl Med Mol Imaging.2014;4(5):426-434.
23. Janssen I, Blanchet EM, Adams K, et al. Superiority of
[68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the
Localization of SDHB-Associated Metastatic Pheochromocytoma and
Paraganglioma. Clin Cancer Res. 2015;21(17):3888-3895.
24. Janssen I, Chen CC, Millo CM, et al. PET/CT comparing
(68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with
CT/MRI for the localization of sporadic metastatic pheochromocytoma and
paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-1791.
25. Fonte JS, Robles JF, Chen CC, et al. False-negative (1)(2)(3)I-MIBG
SPECT is most commonly found in SDHB-related pheochromocytoma or
paraganglioma with high frequency to develop metastatic disease.Endocr Relat Cancer. 2012;19(1):83-93.
26. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG
Scintigraphy in Paraganglioma. Neuroendocrinology.2010;91(1):94-100.
27. Swensen SJ, Brown ML, Sheps SG, et al. Use of 131I-MIBG scintigraphy
in the evaluation of suspected pheochromocytoma. Mayo Clin Proc.1985;60(5):299-304.
28. Taieb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindie E.
Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl
Med. 2012;53(2):264-274.
29. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of
(177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med.2017;376(2):125-135.
30. Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular
imaging and theranostics in neuroendocrine neoplasms. Eur J
Cancer. 2021;146:56-73.
31. Subramaniam RM, Bradshaw ML, Lewis K, Pinho D, Shah C, Walker RC.
ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT
for Neuroendocrine Tumors. Clin Nucl Med. 2018;43(12):899-908.
32. Swami M. Hypoxia: The HIF2alpha puzzle. Nat Rev Cancer.2010;10(9):603.
33. Tarade D, Robinson CM, Lee JE, Ohh M. HIF-2alpha-pVHL complex
reveals broad genotype-phenotype correlations in HIF-2alpha-driven
disease. Nat Commun. 2018;9(1):3359.
34. Hayashi Y, Yokota A, Harada H, Huang G.
Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible
factor-1alpha in cancer. Cancer Sci. 2019;110(5):1510-1517.
35. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive Molecular
Characterization of Pheochromocytoma and Paraganglioma. Cancer
Cell. 2017;31(2):181-193.
36. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured
human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54(6):855-860.
FIGURE LEGENDS
Figure 1 : Metastatic paraganglioma. Fused axial PET
and CT images from 18F-FDG PET/CT at diagnosis (A)
demonstrate a large heterogeneous retroperitoneal mass (circle) with
central photopenia and hypoattenuation suggestive of necrosis (*).
Multiple lung nodules were seen by CT (B, white arrow), the largest of
which were FDG avid (C, black arrow), consistent with metastatic
disease. Coronal MIP image shows no FDG avid disease elsewhere (D).
Coronal MIP image from 68Ga-DOTATATE PET/CT (E) shows
widespread skeletal metastatic disease (red arrows), none of which was
present on the 18F-FDG PET/CT (D). Coronal static
planar image from 123I-MIBG scan (F) revealed
MIBG-avid metastatic disease in the calvarium, axial, and appendicular
skeleton, although the image quality is inferior to the DOTATATE PET/CT
and the overall disease burden is underestimated by123I-MIBG. Although some lesions not seen by planar
imaging were discernable by SPECT/CT, many lesions seen by68Ga-DOTATATE PET, for example in the liver, ribs,
humeral shafts, femoral shafts, and tibiae (arrows) were not evident by123I-MIBG scintigraphy.
Figure 2: Cancer predisposition with SDHC germline
mutation and co-existing GIST and paraganglioma.18F-FDG PET MIP images (A) demonstrates diffuse
metastatic disease from the patient’s known gastrointestinal stromal
tumor. Axial contrast-enhanced CT and 18F-FDG PET
images (B, C) highlight numerous hepatic masses with varying degrees of18F-FDG avidity (red arrows), complicating the
detection of new lesions with a different histology. Axial non-contrast
CT and 68Ga-DOTATATE PET images (E, F) reveal an
intensely avid mass in the porta hepatis (circle), consistent with
paraganglioma. The adjacent lesions that had been FDG-avid on the
earlier 18F-FDG PET/CT (white arrow) showed no
DOTATATE uptake, indicating co-existing GIST and paraganglioma in the
same patient. The paraganglioma was resected surgically; the patient
continues on medical therapy for his metastatic GIST.
The low attenuation region near the periphery that has neither FDG nor
DOTATATE uptake (*) represents a site of prior RF ablation.
Figure 3: Cancer predisposition associated with polycythemia and
multiple functional paragangliomas (Pacak-Zhuang syndrome).18F-FDG PET/CT was obtained for restaging after
surveillance wbMRI revealed new sites of disease. Coronal18F-FDG PET MIP image (A) and axial fused PET/CT
images (D) from 18F-FDG PET/CT, demonstrate increased18F-FDG uptake in the left suprarenal mass (B, arrow)
seen by MRI. Multiple additional foci of FDG uptake, for example in an
aortocaval lesion (A, D: circle), were also concerning for
paraganglioma, and even in retrospect were difficult to convincingly see
by MRI (C).
18F-FDG PET/CT obtained six months later when serum
catecholamine and chromogranin A levels were continuing to rise, was
markedly limited for evaluation of metastatic lesions, secondary to
intensely FDG-avid hypermetabolic brown adipose tissue uptake, best
illustrated on the coronal MIP image (E) from the FDG PET/CT.
Given the patient’s hyper-catecholamine secreting state resulting from
her underlying HIF2A activating mutation, she was started on
molecularly targeted therapy. 68Ga-DOTATATE PET/CT,
obtained just 17 days after drug initiation (F), showed no background
brown fat uptake and demonstrated the suprarenal lesion (arrow) and
aorto-caval lesion (circle), with the suprarenal lesion having already
decreased slightly in size in response to targeted therapy. She
continues on treatment and has been monitored by surveillance MRI and68Ga-DOTATATE PET/CT.
Figure 4: Proposed algorithm for68Ga-DOTATATE imaging children with known PPGL or PPGL
predisposition syndrome.